CorMedix Inc (CRMD)

[axelvento]

Drug Opportunities in Oncology
CMDX-001
Q3 BIG NEWS OUT!
stay tuned


In vitro studies indicate that taurolidine has a direct and selective antineoplastic effect on glial and neuronal brain tumor cells, and in addition, has been shown to significantly enhance the activity of cytotoxic cancer drugs, including vincristine.

In 2017, CorMedix announced a collaboration with the Pediatric Oncology Therapeutic Investigators Consortium (POETIC) to evaluate a novel formulation of taurolidine (CMDX-001) as a part of an investigational therapy for rare pediatric cancers including neuroblastoma and osteosarcoma.

Pediatric neuroblastoma, an Orphan Disease in the United States, is an adrenal cancer that develops in the nerve cells of the medulla and is the most common extracranial tumor in childhood, usually occurring in infants and children under 10.

CorMedix and POETIC are advancing this program through preclinical studies and will determine a potential clinical strategy once in vivo proof-of-concept is achieved.